• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Observational Studies Key to Resolving Medication Safety Gaps in Pregnancy

by
November 16, 2026
in Health
Reading Time: 5 mins read
0
Observational Studies Key to Resolving Medication Safety Gaps in Pregnancy

Observational Studies Key to Resolving Medication Safety Gaps in Pregnancy

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Observational studies represent the most effective and timely approach to resolving persistent evidence gaps surrounding the safety of medication use during pregnancy, according to an editorial published in PLOS Medicine by Jennifer Jardine and Suzanne de Bruijn on behalf of the journal staff editors. Pregnant individuals have historically been excluded from clinical trials, leaving safety data scarce despite widespread drug use during pregnancy.

Medication use during pregnancy is prevalent across global populations, with a recent systematic review cited in the editorial estimating that 56 percent of pregnant individuals take prescribed medications, although estimates vary widely across settings. Antiemetics, antibiotics, and analgesics are the medications most commonly consumed. Furthermore, the true rate of exposure is expected to be higher when over-the-counter preparations and nutritional supplements are accounted for, and this figure is anticipated to rise further as global trends show individuals increasingly having children later in life when comorbidities requiring pharmacological management are more frequent.

The historical caution surrounding pharmacological intervention during gestation stems from notable adverse historical events. The thalidomide disaster of the 1950s and 1960s, in which a drug prescribed for morning sickness caused fetal abnormalities and miscarriage, remains a searing reminder of potential gestational risks. In more recent decades, research has documented associations between antiepileptic therapies and neurocognitive delay in offspring, alongside publicized concerns assessing potential associations between paracetamol or acetaminophen exposure and neurodevelopmental differences.

Because pregnant populations have historically been excluded from standard clinical trials, the vast majority of existing safety data derives from observational investigations. Recent observational analyses published in PLOS Medicine have provided reassurance for several common exposures. For instance, a study led by Hasidim and colleagues identified no association between first-trimester exposure to nonsteroidal anti-inflammatory drugs, including ibuprofen, and major congenital malformations. Similarly, recent investigations evaluating antibiotic treatments found no association between first-trimester macrolide administration and major malformations, nor between general antibiotic exposure and childhood autoimmune conditions.

Conversely, other observational studies have highlighted potential associations that require cautious interpretation. A meta-analysis conducted by Shakhshir and colleagues observed an association between maternal exposure to beta-2-adrenergic agonists—the most commonly prescribed inhaled medications for managing asthma—and autism spectrum disorder in offspring. However, the study authors emphasized that these findings remain inconclusive because confounding by indication cannot be excluded, underscoring the methodological complexities inherent in observational epidemiological designs.

Confounding by indication poses a central obstacle in drawing definitive safety conclusions from observational cohorts. For a pregnant individual, treating an underlying chronic or acute condition is frequently safer than withholding pharmacological therapy. Maternal physical wellbeing directly influences fetal health, meaning potential drug exposure risks must be balanced against the consequences of unmanaged disease. Mothers experiencing severe, untreated illness face elevated risks of miscarriage, and their infants are statistically more likely to be delivered preterm or small for gestational age.

The clinical risk-benefit calculation varies substantially depending on the maternal health condition. For diseases where maternal treatment yields distinct and essential benefits, such as cystic fibrosis and epilepsy, the justification for delaying therapy to await long-term fetal outcome data is considerably weaker. In contrast, temporary cessation of treatment carries far fewer adverse consequences for conditions such as dermatoses or mild allergies. Additionally, certain critical endpoints, particularly subtle neurodevelopmental alterations, require years of longitudinal observation to emerge, while public health crises such as the COVID-19 pandemic force clinical decisions to be made before empirical evidence can be accumulated.

Traditional clinical trials have offered minimal resolution to this evidentiary gap. Between 2019 and 2023, pregnant individuals were represented in only 1.1 percent of clinical trial applications submitted to the regulatory authority in the United Kingdom, preventing early trial safety and efficacy observations from being translated to pregnant populations. Although regulatory agencies including the United States Food and Drug Administration and the European Medicines Agency have updated guidelines to support the inclusion of pregnant participants in specific scenarios, regulatory permission alone does not eliminate structural design hurdles.

Trial designs involving pregnancy face intricate practical and statistical challenges. In standard clinical studies, relatively few participants become pregnant, and those who do may remain pregnant for only a fraction of the study timeframe. Moreover, normal gestational physiological adaptations increase the probability of developing secondary complications or novel clinical conditions. Consequently, adequately powering a clinical trial to evaluate pregnant participants requires enrolling substantially larger patient cohorts, particularly to ensure sufficient statistical power for independent subgroup analyses within the pregnant cohort.

Consequently, observational research utilizing administrative databases and modern target trial emulation remains indispensable for pharmacovigilance. However, as noted in a Perspective by Yuen and Man, observational methodologies face the profound challenge that temporal relationships are rarely straightforward. Both pharmacological exposures and the physiological state of pregnancy continuously evolve across gestational time. Accurate epidemiological analyses demand sophisticated statistical modeling of time-varying exposures, concomitant medications, underlying maternal illnesses, and the progressive stages of gestation.

Geographical and infrastructural disparities further constrain current observational evidence. Because robust observational investigations depend upon extensive healthcare registries and reliable record linkage between maternal and pediatric medical records, such studies are presently concentrated in higher-income nations. Findings generated within these well-resourced environments may not translate seamlessly to low-income regions, where distinct socioeconomic, nutritional, and clinical factors alter interactions between pharmacological treatments and health outcomes for mothers and infants.

To accelerate evidence generation, the editorial authors recommend several systematic improvements to data infrastructure and regulatory frameworks. Health systems require centralized reporting mechanisms capable of capturing all pregnancy-related medication data in a single location, including accidental exposures during trials, pre-pregnancy pharmaceutical usage, case reports, and documentation from teratology services such as the European Network of Teratology Information Services. Registries must capture granular exposure details, specifically exact gestational age and dosage metrics, while harmonizing standards across international registries and enhancing pediatric linkage.

Epidemiological registries should be systematically paired with mechanistic pharmacological methodologies to assess biological plausibility. Techniques including ex vivo human placental perfusion, cellular assays, and physiologically based pharmacokinetic modeling can quantify whether and when a compound crosses the placental barrier. Measuring drug exposure biomarkers in umbilical cord blood, neonatal blood spots, and infant hair samples provides direct biological verification of fetal exposure, helping researchers prioritize urgent safety investigations.

Ultimately, establishing standardized methodological frameworks tailored to specific drug classes is essential to interpret complex observational datasets. Defining perinatal intervals and accurately capturing early pregnancy losses present substantial logistical difficulties that require international scientific consensus. Jardine and de Bruijn conclude that concerted, collaborative efforts to strengthen medication safety evidence will directly improve maternal and fetal outcomes, alleviate anxiety surrounding necessary treatments, and promote health equity for pregnant populations worldwide.

A primary policy recommendation put forward in the editorial involves enacting statutory requirements that mandate commercial pharmaceutical manufacturers to conduct comprehensive registry studies for every medication introduced to the market. Currently, post-marketing drug safety evaluations in pregnant populations frequently rely on independent academic investigators and charitable grant funding to bridge substantial evidence deficits.

Subject of Research: Evidence gaps and research methodologies for evaluating medication safety during pregnancy

Article Title: Towards improving the safety of medication use in pregnancy

Article References: Jardine, J., de Bruijn, S., & on behalf of the PLOS Medicine staff editors (2026). Towards improving the safety of medication use in pregnancy. PLOS Medicine, 23(11), e1005291. https://doi.org/10.1371/journal.pmed.1005291

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1005291

Keywords: medication safety, pregnancy, observational studies, clinical trials, confounding by indication, pharmacovigilance, teratology, placental perfusion, pharmacokinetic modelling, maternal health, fetal exposure, health equity, birth registries, macrolides, nonsteroidal anti-inflammatory drugs, antiepileptics, paracetamol, beta-2-adrenergic agonists

News Source: Harold Sullivan. (November 16, 2026). Observational Studies Key to Resolving Medication Safety Gaps in Pregnancy. Scienmag.

Tags: antiepilepticsbeta-2-adrenergic agonistsbirth registriesClinical Trialsconfounding by indicationfetal exposurehealth equitymacrolidesMaternal HealthMedication safetynonsteroidal anti-inflammatory drugsobservational studiesparacetamolpharmacokinetic modellingPharmacovigilanceplacental perfusionPregnancyteratology
Share12Tweet7Share2ShareShareShare1

Related Posts

Study Analyzes Adaptive Rollout of Molecular Tuberculosis Tests Across the Philippines

Study Analyzes Adaptive Rollout of Molecular Tuberculosis Tests Across the Philippines

November 19, 2026
Exercise Benefits for Psychological Distress in Lung Cancer Remain Highly Uncertain

Exercise Benefits for Psychological Distress in Lung Cancer Remain Highly Uncertain

November 19, 2026

Investigational mRNA Flu Vaccine Generates Dual Antigen Immunity in Phase Two Trial

November 19, 2026

Decision Model Defines Economic Benchmarks for Breast Cancer Psychosocial Rehabilitation

November 19, 2026

POPULAR NEWS

  • Lifelong Social Isolation Tied to Muscle Weakness but Lower Obesity Odds

    Lifelong Social Isolation Tied to Muscle Weakness but Lower Obesity Odds

    29 shares
    Share 12 Tweet 7
  • Narrative Review Identifies Systematic Bias and Privacy Risks Across AI Electrocardiography Protocols

    29 shares
    Share 12 Tweet 7
  • Landscape Integrated Farming Framework Links Cross-Farm Resources to Enhance Climate Resilience

    29 shares
    Share 12 Tweet 7
  • Machine Learning Matches Traditional Time Series in Forecasting Tanzanian Sisal Exports

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study Analyzes Adaptive Rollout of Molecular Tuberculosis Tests Across the Philippines

Exercise Benefits for Psychological Distress in Lung Cancer Remain Highly Uncertain

Study Quantifies Multidisciplinary Clinical Burden in Von Hippel-Lindau Central Nervous System Tumors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.